People get into a heavy-duty sin and guilt trip, feeling that if things are going wrong, that means that they did something bad and they are being punished. That’s not the idea at all. The idea of karma is that you continually get the teachings that you need to open your heart. To the degree that you didn’t understand in the past how to stop protecting your soft spot, how to stop armoring your heart, you’re given this gift of teachings in the form of your life, to give you everything you need to open further.
I no longer believed in the idea of soul mates, or love at first sight. But I was beginning to believe that a very few times in your life, if you were lucky, you might meet someone who was exactly right for you. Not because he was perfect, or because you were, but because your combined flaws were arranged in a way that allowed two separate beings to hinge together.
NASA astronaut Reid Wiseman captured this image of Florida to Louisiana just before dawn, taken from the International Space Station, and posted it to social media on Friday, Sept. 12. Wiseman, Commander Max Suraev and Flight Engineer Alexander Gerst began their first full workweek Monday as a three-person crew aboard the space station, while the three additional flight engineers who will round out the Expedition 41 crew spent the day training for next week’s launch to the orbiting complex.
Ahhh, love seeing my state from space :)
I love seeing the homeworld from space. :)
Fuuuuuck. I’m low on space on my phone as it is.
If you download and install iOS 8 using iTunes instead of “over the air” you don’t need to worry about freeing up space on your iPhone.
But, do I still have to worry about iCloud leaking naked pictures of U2 into my iPhoto library?
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
The new antibody targets ROR1, a protein used by embryonic cells during early development and exploited by cancer cells to promote tumor growth and metastasis, the latter responsible for 90 percent of all cancer-related deaths.
Because ROR1 is not expressed by normal adult cells, scientists believe it is a biomarker of cancer cells in general and cancer stem cells in particular. Because it appears to drive tumor growth and disease spread, they believe it also presents an excellent target for anti-cancer therapy.
Developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, who holds the Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues, the antibody is called cirmtuzumab (also known as UC-961). In previous animal studies, Kipps’ team reported that ROR1 is singularly expressed on CLL and also on a variety of different cancers, including cancers of the breast, pancreas, colon, lung and ovary. In mouse models of CLL, ROR1 acts as an accelerant when combined with another oncogene to produce a faster-growing, more aggressive cancer.
Cirmtuzumab was developed under the auspices of the California Institute for Regenerative Medicine’s HALT leukemia grant awarded to Dennis Carson, MD, principal investigator, and Catriona Jamieson, MD, PhD, co-principal investigator to develop six distinct therapies against cancer stem cells. Kipps led one of the six projects and generated antibodies against ROR1, leading to the cirmtuzumab trial in patients with CLL.
“The primary goal of this phase I clinical trial is to evaluate whether cirmtuzumab is a safe and well-tolerated cancer stem cell-targeted agent in patients with CLL,” said Jamieson, chief of the Division of Regenerative Medicine, associate professor of medicine, director of stem cell research at UC San Diego Moores Cancer Center, deputy director of the Sanford Stem Cell Clinical Center and a principal investigator of the cirmtuzumab clinical trial.
Michael Choi, MD, assistant clinical professor of medicine and co-principal investigator of the clinical trial said, “The trial will involve patients with relapsed or refractory CLL, who will receive an intravenous infusion every 14 days at Moores, followed by regular monitoring and clinic visits to assess efficacy and identify and manage any adverse effects. Initial treatment is planned for two months.”
To learn more about eligibility for this clinical trial, call Reilly L. Kidwell at 858-534-4801 or Samuel Zhang at 858-534-8127.
With the outsourcing of most traditional manufacturing jobs and the rise of the service economy, in which most people who work stare into a screen all day — whether they work at Target or on Wall Street — has come a set of cultural shifts Scott does not mention. Work and entertainment exist on a continuum with no clear dividing line between the two, and the distinction between producer and consumer has become confused. Indeed, an individual citizen’s most important economic role, in the post-industrial West, is that of a consumer, inhaling goods, products, services and entertainment, as much of that as possible delivered electronically or shipped to your door. (Consumption power has grown even as real income has fallen and inequality has grown, one of the many paradoxes in late capitalism.) Being a producer in the old-fashioned sense comes second if it comes at all. Many of us — myself and A.O. Scott very much included — produce things that aren’t even things, and whose exchange-value and social utility are nebulous at best.